{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:46:42Z","timestamp":1785426402159,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian Pediatr"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13312-026-00311-w","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:28:43Z","timestamp":1775716123000},"page":"311-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2025) and Update on Immunization for Children Aged 0 Through 18 Years"],"prefix":"10.1007","volume":"63","author":[{"given":"Digant D.","family":"Shastri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi Kant","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rajsekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumitha","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Mohan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapan Kumar","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Krishna Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhadresh R.","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Gangakhedkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwar","family":"Dayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Bade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. V.","family":"Basavaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant","family":"Khalatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh N.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"311_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s13312-024-3104-5","volume":"61","author":"MIS Rao","year":"2024","unstructured":"Rao MIS, Kasi SG, Dhir SK, et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2023) and Update on Immunization for Children aged 0 Through 18 Years. Indian Pediatr. 2024;61:113\u201325.","journal-title":"Indian Pediatr"},{"key":"311_CR2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073620","volume":"156","author":"Committee on Infectious Diseases","year":"2025","unstructured":"Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2025\u20132026: Policy Statement. Pediatrics. 2025;156:e2025073620.","journal-title":"Pediatrics"},{"key":"311_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00066-1","volume":"5","author":"S Caini","year":"2024","unstructured":"Caini S, Meijer A, Nunes MC, et al. Probable extinction of influenza B\/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases. Lancet Microbe. 2024;5:100851.","journal-title":"Lancet Microbe"},{"key":"311_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s13312-025-00119-0","volume":"62","author":"VM Vashishtha","year":"2025","unstructured":"Vashishtha VM, Kumar P. Optimizing influenza vaccine protection in India. Indian Pediatr. 2025;62:769\u201374.","journal-title":"Indian Pediatr"},{"key":"311_CR5","unstructured":"Recommended composition of influenza virus vaccines for use in the 2025\u20132026 northern hemisphere influenza season. World Health Organisation. Accessed December 28, 2025. Available from: https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2025-2026-nh-influenza-season."},{"key":"311_CR6","unstructured":"Recommended composition of influenza virus vaccines for use in the 2026 southern hemisphere influenza season. World Health Organisation. Accessed December 28, 2025. Available from: https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2026-southern-hemisphere-influenza-season."},{"issue":"32","key":"311_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.15585\/mmwr.mm7432a2","volume":"74","author":"LA Grohskopf","year":"2025","unstructured":"Grohskopf LA, Blanton LH, Ferdinands JM, Reed C, Dugan VG, Daskalakis DC. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices\u2013United States, 2025\u201326 Influenza Season. MMWR Morb Mortal Wkly Rep. 2025;74:500\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"311_CR8","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1016\/j.vaccine.2021.07.073","volume":"39","author":"KM Vadrevu","year":"2021","unstructured":"Vadrevu KM, Raju D, Rani S, et al. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination. Vaccine. 2021;39:6682\u201390.","journal-title":"Vaccine"},{"key":"311_CR9","first-page":"193","volume":"100","author":"World Health Organisation","year":"2025","unstructured":"World Health Organisation. WHO Position Paper on Immunization to Protect Infants Against Respiratory Syncytial Virus Disease. Wkly Epidemiol Rec. 2025;100:193\u2013218.","journal-title":"Wkly Epidemiol Rec"},{"key":"311_CR10","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073923","volume":"156","author":"Committee on Infectious Diseases","year":"2025","unstructured":"Committee on Infectious Diseases. Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement. Pediatrics. 2025;156:e2025073923.","journal-title":"Pediatrics"},{"key":"311_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, et al. Single-dose Nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415\u201325.","journal-title":"N Engl J Med"},{"key":"311_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/cid\/ciae596","volume":"81","author":"D Arbetter","year":"2025","unstructured":"Arbetter D, Gopalakrishnan V, Aksyuk AA, et al. Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: analysis from a phase 3 randomized clinical trial (MELODY). Clin Infect Dis. 2025;81:634\u201344.","journal-title":"Clin Infect Dis"},{"key":"311_CR13","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","volume":"389","author":"SB Drysdale","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389:2425\u201335.","journal-title":"N Engl J Med"},{"key":"311_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581970","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Kong L, Liu X, Wu P, Zhang L, Ding F. Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis. Front Immunol. 2025;16:1581970.","journal-title":"Front Immunol"},{"key":"311_CR15","unstructured":"Beyfortus. Food and Drug Administration. Label. Accessed on February 20, 2026. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761328s000lbl.pdf"},{"key":"311_CR16","unstructured":"Beyfortus. European medics Agency. Beyfortus. Accessed on February 20, 2026. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus"},{"key":"311_CR17","unstructured":"Beyfortus. Central Drugs Standard Control Organization. Accessed on February 20, 2026. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCTApprovals\/17.%20Sanofi_%20Nirsevimab.pdf"},{"key":"311_CR18","unstructured":"Cervical Cancer Elimination Initiative [Internet]. Accessed on February 24, 2026. Available from: https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative"},{"key":"311_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100056","volume":"1","author":"RV Barnabas","year":"2022","unstructured":"Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022;1:EVIDoa2100056.","journal-title":"NEJM Evid"},{"key":"311_CR20","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","volume":"29","author":"RV Barnabas","year":"2023","unstructured":"Barnabas RV, Brown ER, Onono MA, et al. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat Med. 2023;29:3224\u201332.","journal-title":"Nat Med"},{"key":"311_CR21","doi-asserted-by":"publisher","first-page":"e1473","DOI":"10.1016\/S2214-109X(22)00309-6","volume":"10","author":"D Watson-Jones","year":"2022","unstructured":"Watson-Jones D, Changalucha J, Whitworth H, et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. Lancet Glob Health. 2022;10:e1473\u201384.","journal-title":"Lancet Glob Health"},{"key":"311_CR22","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1016\/j.vaccine.2017.12.078","volume":"36","author":"AR Kreimer","year":"2018","unstructured":"Kreimer AR, Herrero R, Sampson JN, et al. Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV-vaccine trial and future research studies. Vaccine. 2018;36:4774\u201382.","journal-title":"Vaccine"},{"key":"311_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/jncimonographs\/lgae042","volume":"2024","author":"SG Malvi","year":"2024","unstructured":"Malvi SG, Esmy PO, Muwonge R, et al. A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination. J Natl Cancer Inst Monogr. 2024;2024:317\u201328.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"311_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jncimonographs\/lgae032","volume":"2024","author":"C Porras","year":"2024","unstructured":"Porras C, Romero B, Kemp T, et al. HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. J Natl Cancer Inst Monogr. 2024;2024:329\u201336.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"311_CR25","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/S1473-3099(25)00284-1","volume":"25","author":"B Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s B, Ocampo R, Porras C, et al. Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial. Lancet Infect Dis. 2025;25:1314\u201324.","journal-title":"Lancet Infect Dis"},{"key":"311_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jnci\/djad263","volume":"116","author":"TJ Palmer","year":"2024","unstructured":"Palmer TJ, Kavanagh K, Cuschieri K, et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. J Natl Cancer Inst. 2024;116:857\u201365.","journal-title":"J Natl Cancer Inst"},{"key":"311_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2024.100486","volume":"19","author":"HS Whitworth","year":"2024","unstructured":"Whitworth HS, Mounier-Jack S, Choi EM, et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: an updated systematic review of evidence from clinical trials. Vaccine X. 2024;19:100486.","journal-title":"Vaccine X"},{"key":"311_CR28","unstructured":"Fact Sheet: CDC Childhood Immunization Recommendations. US Department of Health & Human Services. Accessed on Feb 12, 2026. Available from: https:\/\/www.hhs.gov\/press-room\/fact-sheet-cdc-childhood-immunization"},{"key":"311_CR29","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","volume":"36","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Rabies Vaccines: WHO Position Paper, April 2018\u2013Recommendations. Vaccine. 2018;36:5500\u20133.","journal-title":"Vaccine"},{"key":"311_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s13312-021-2096-7","volume":"58","author":"SG Kasi","year":"2021","unstructured":"Kasi SG, Shivananda S, Marathe S, et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2020\u201321) and Update on Immunization for Children Aged 0 Through 18 Years. Indian Pediatr. 2021;58:44\u201353.","journal-title":"Indian Pediatr"},{"key":"311_CR31","unstructured":"National Centre for Disease Control, Ministry of Health and Family Welfare, Government of India. National Guidelines for Rabies Prophylaxis. 2019. Accessed on December 28, 2025. Available from: https:\/\/ncdc.mohfw.gov.in\/wp-content\/uploads\/2025\/06\/Rabies-Guidelines.pdf."},{"issue":"1","key":"311_CR32","doi-asserted-by":"publisher","first-page":"A107","DOI":"10.1016\/j.vaccine.2019.01.041","volume":"37","author":"J Kessels","year":"2019","unstructured":"Kessels J, Tarantola A, Salahuddin N, Blumberg L, Knopf L. Rabies post-exposure prophylaxis: a systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course. Vaccine. 2019;37:A107\u201317.","journal-title":"Vaccine"},{"key":"311_CR33","unstructured":"Summary of product characteristics. MenFive. Meningococcal (A, C, Y, W, X) Polysaccharide Conjugate Vaccine (Freeze-Dried). 2022. Serum Institute of India Pvt. Ltd. Accessed on December 30, 2025. Available from https:\/\/share.google\/rHt9VqPjEhohnv3a7"},{"key":"311_CR34","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1056\/NEJMoa2214924","volume":"388","author":"FC Haidara","year":"2023","unstructured":"Haidara FC, Umesi A, Sow SO, et al. Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. N Engl J Med. 2023;388:1942\u201355.","journal-title":"N Engl J Med"},{"key":"311_CR35","unstructured":"Details of Manufacturing Permissions of Human Vaccines. CDSCO. Accessed on February 24, 2026. Available from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=MTM4NTg="},{"key":"311_CR36","unstructured":"Prequalification of MenFiveTM. WHO\u2014Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). Accessed on February 24, 2026. Available from: https:\/\/extranet.who.int\/prequal\/vaccines\/p\/menfivetm"},{"key":"311_CR37","unstructured":"Product monograph including patient medication information. Beyfortus\u00ae Sanofi Pasteur Limited. 2024. Accessed on December 28, 2025. Available from https:\/\/share.google\/tTFJ6P6XT03eQzo70"},{"key":"311_CR38","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1016\/j.vaccine.2023.08.084","volume":"41","author":"SK Susarla","year":"2023","unstructured":"Susarla SK, Gupta M, Uttam KG, et al. Immunogenicity and safety of Havisure\u2122 vaccine developed by human biologicals institute in healthy subjects of 12 months to 49 years of age: a phase II\/III, randomized, single blind, non-inferiority study. Vaccine. 2023;41:6215\u201320.","journal-title":"Vaccine"},{"key":"311_CR39","unstructured":"Summary of product characteristics (SMPC). Havisure. 2023. Human Biologicals Institute. Accessed on December 28, 2025. Available from: https:\/\/share.google\/9sbpVOZv0XZgiK44b"},{"key":"311_CR40","unstructured":"Summary of product characteristics (SMPC). ROTAVAC5D\u00ae. Bharat Biotech Private Limited. 2024. Accessed on December 28, 2025. Available from: https:\/\/share.google\/ns2hPIS2fddE1UQXh"},{"key":"311_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2278346","volume":"19","author":"KK P","year":"2023","unstructured":"P KK, Chiteti SR, Aileni VK, et al. Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC\u00ae liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC\u00ae (frozen formulation) in healthy infants. Hum Vaccin Immunother. 2023;19:2278346.","journal-title":"Hum Vaccin Immunother"},{"key":"311_CR42","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1016\/j.vaccine.2021.04.060","volume":"39","author":"R Chilengi","year":"2021","unstructured":"Chilengi R, Mwila-Kazimbaya K, Chirwa M, et al. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC\u00ae and ROTAVAC 5D\u00ae in Zambian infants. Vaccine. 2021;39:3633\u201340.","journal-title":"Vaccine"},{"key":"311_CR43","unstructured":"Summary of product characteristic (SMPC) Pneumococcal Polysaccharide Conjugate Vaccine I.P. (PCV13 - TT). 2024. Accessed on December 28, 2025. Available from: https:\/\/share.google\/8UWXMn3OrctLYgpJV"},{"key":"311_CR44","unstructured":"PREVNAR 20\u00ae (Pneumococcal 20-valent Conjugate Vaccine), suspension for intramuscular injection. Package insert. 2021. Pfizer Inc. Accessed on December 28, 2025. Available from: https:\/\/share.google\/SMv2mc27ydSvohfJl"},{"key":"311_CR45","volume-title":"IAP Guidebook on Immunization 2025","author":"S Nayak","year":"2025","unstructured":"Nayak S, Khadke R. Pneumococcal vaccines. In: Shastri DD, Dhir SK, editors. IAP Guidebook on Immunization 2025. 5th ed. New Delhi: Jaypee Brothers; 2025.","edition":"5"}],"container-title":["Indian Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-026-00311-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13312-026-00311-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-026-00311-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:05:04Z","timestamp":1777273504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13312-026-00311-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1007\/s13312-026-00311-w","relation":{},"ISSN":["0019-6061","0974-7559"],"issn-type":[{"value":"0019-6061","type":"print"},{"value":"0974-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}